18 F]Nifene is an agonist PET radioligand developed to image a4b2* nicotinic acetylcholine receptors (nAChRs). This work aims to quantify the receptor density (B max ) of a4b2* nAChRs and the in vivo (apparent) dissociation constant (K Dapp ) of [ 18 F]nifene. Multiple-injection [ 18 F]nifene experiments with varying cold nifene masses were conducted on four rhesus monkeys with a microPET P4 scanner. Compartment modeling techniques were used to estimate regional B max values and a global value of K Dapp . The fast kinetic properties of [ 18 F]nifene also permitted alternative estimates of B max and K Dapp at transient equilibrium with the same experimental data using Scatchard-like methodologies. Averaged across subjects, the compartment modeling analysis yielded B max values of 4.8 ± 1.4, 4.3 ± 1.0, 1.2 ± 0.4, and 1.2 ± 0.3 pmol/mL in the regions of antereoventral thalamus, lateral geniculate, frontal cortex, and subiculum, respectively. The K Dapp of nifene was 2.4 ± 0.3 pmol/mL. The Scatchard analysis based on graphical evaluation of the data after transient equilibrium yielded B max estimations comparable to the modeling results with a positive bias of 28%. These findings show the utility of [ 18 F]nifene for measuring a4b2* nAChR B max in vivo in the rhesus monkey with a single PET experiment.
INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligandgated ion channels distributed throughout the central nervous system. The a4b2 subtype is the most abundant subtype of this receptor system. Abnormal a4b2 nAChR pathologies have been associated with a variety of neuropsychiatric processes and diseases, including neurodevelopmental deficiencies and substance abuse. Reductions in a4b2 nAChR binding have been found in patients with autism, 1 Parkinson's disease, 2 Alzheimer's disease, 3 and depressive disorder, 4 whereas increased a4b2 nAChR binding was observed in abstaining smokers. 5 Quantitative binding metrics such as the binding potential based on nondisplaceable uptake (BP ND ) depend on both receptor density (B max ) and in vivo (apparent) ligand-receptor affinity (1/K Dapp ). 6 In the case of Alzheimer's disease, Sihver and coworkers 7 used in vitro procedures to find that reductions in a4b2* nAChR binding resulted from decreases in B max . Conversely, lower in vivo radiotracer uptake levels found in patients with major depressive disorder analyzed in conjunction with in vitro data determined the in vivo binding reductions to result from greater concentrations of extracellular acetylcholine, which would increase K Dapp . 4 The ability to perform purely in vivo measurements of B max and K Dapp would provide a vastly improved understanding of longitudinal changes to a4b2* nAChRs and synaptic acetylcholine levels related to neuropathologies.
Regional measurements throughout the brain of a4b2* nAChR B max have been made with different radioligands in a variety of species. The notation a4b2* denotes small amounts of binding to other nAChR subtypes that include the a4 or b2 subunits. Reported B max values observed with in vitro techniques include experiments with 5-[ 125 I]IA-85380 in humans 8 and [ 3 H]epibatidine in rats. 9 A variety of tritiated ligands were also used for this measurement in the cortex of postmortem human tissue. 10 Each of these studies found the largest receptor density to be present in the thalamus, particularly the lateral geniculate nucleus and antereoprincipal thalamic nucleus. Experiments were also performed using 2-[ 18 F]FA-85380 (2-[ 18 F]FA) to measure B max in vivo with the PET multiple-injection (MI) approach in baboons. 11 In vivo B max measurements with 2-[ 18 F]FA are hindered by slow kinetics, resulting in scanning protocols lasting 270 minutes. 11 [ 18 F]Nifene is an analog radioligand of 2-[ 18 F]FA with faster kinetic properties, as [ 18 F]nifene attains transient equilibrium in the thalamus within 30 minutes while maintaining elevated binding consistent with a4b2* nAChR distribution in the rhesus monkey brain. 12, 13 Further experiments showed rapid displacement of [ 18 F]nifene by nicotine. 14 The fast displacement of [ 18 F]nifene by competing ligands indicates possible sensitivity to acetylcholinesterase inhibitors, a desirable yet elusive trait of PET a4b2* nAChR radioligands. These kinetic properties of [ 18 F]nifene make it a promising candidate to interrogate the a4b2* nAChR system in vivo with simplified experimental protocols.
The aims of this work were, first, to exploit the fast kinetic properties of [ 18 F]nifene and develop an optimized MI experimental design to measure a4b2* nAChR B max in vivo in the rhesus monkey model with PET. The experiments were analyzed with compartment modeling to provide B max and K Dapp measurements. As the optimal MI experimental design provided transient equilibrium of three [ 18 F]nifene injections at varying specific activities, B max was also evaluated with a Scatchard-based analysis method. An additional aim was to evaluate the different analysis methods to provide a comparison of the methods for accurate B max evaluation while considering experimental complexity. Ultimately, quantification of a4b2* nAChR B max and the K Dapp of [ 18 F]nifene would allow for the development of sensitive experiments to detect small changes to the a4b2* nAChR system for applications involving disease models or pharmacological intervention.
MATERIALS AND METHODS Radiochemistry
The production of [ 18 F]nifene was performed following previously published methods. 13 Briefly, nucleophilic substitution of the nitro precursor with [ 18 F]fluoride was performed, followed by purification of the N-boc-[ 18 F]nifene intermediate with high-performance liquid chromatography. The intermediate was then deprotected with hydrochloric acid. The final product was pH balanced to 7.0 with sodium bicarbonate and diluted to a 10 mL volume for final formulation. Overall batch yields ranged from 0.9 to 2.4 GBq, whereas specific activities at the time of first injection were 150 to 550 GBq/mmol. Both the nitro precursor and standard compound were purchased from ABX (Radeberg, Germany). Stock solution of nifene standard with a concentration of 0.1 nmol/mL was prepared for MI studies.
Experimental Design
The D-optimal criterion, described in detail by Salinas and co-workers, 15 was used to maximize the identification and precision of the kinetic parameters B max , k on , and k off to select the optimal MI experimental design. Optimization of MI experiments focused on the thalamic regions of the brain. As the true parameter values were not known a priori, initial parameter estimates ranged from 0.01 to 0.5 mL/pmol per min for k on and 0.05 to 0.5 1/min for k off , with K Dapp constrained to vary between 1.0 and 4.0 pmol/mL. B max ranged from 1.0 to 6.0 pmol/mL, consistent with literature values for thalamic a4b2* nAChR densities. 8, 9, 11 Candidate protocols included both two-and three-injection schemes and varied both the specific activity and the injection times. Arterial input functions from our previous work 13 were used for the optimizations, which were performed with COMKAT software. 16 PET Experiment Data Acquisition PET data were acquired on a Concorde microPET P4 scanner, which has a 7.8-cm axial field of view, 19-cm transaxial field of view, and a reported inplane spatial resolution of 1.75 mm. 17 The actual spatial resolution was 2.80 mm in reconstructed images using the experimental conditions and processing methods reported herein. Scans were performed on a total of four Macaca mulatta (rhesus monkey) subjects (3 female, 1 male; 6.1 to 11.9 kg; 4.6 to 12.9 years; subject names: RH1: BD66; RH2: BD22; RH3: BD67; RH4: AY96). Three subjects received experiments consisting of three [ 18 F]nifene injections (RH1, RH2, and RH3), whereas another experiment was included with two [ 18 F]nifene injections (RH4). Subjects were anesthetized before PET procedures with 10 mg/kg ketamine (intramuscularly), and maintained on 1% to 1.5% isoflurane throughout the experiment. Atropine sulfate was given to minimize secretions. Once anesthetized, the subject was placed in a stereotaxic headholder, and a 518 second transmission scan was acquired with a 57 Co point source. Emission data acquisition was initiated simultaneously with a fast bolus injection of tracer dose [ 18 F]nifene and continued for 105 to 120 minutes. Heart rate, breathing rate, body temperature, and SpO 2 (blood oxygen saturation) levels were monitored throughout the procedure. On experiment completion, the subject was returned to its cage and monitored until fully alert. All housing and experimental guidelines were approved by the institutional animal care and use committee (IACUC). These procedures are in accordance with the stringent regulations encompassing the ethical care and use of laboratory animals, as published in the USDA 'Federal Register' standards, and the 'Guide for the Care and Use of Laboratory Animals' set forth by the NIH (Bethesda, MD, USA).
Measurement of [ 18 F]Nifene in the Blood
Parent [ 18 F]nifene in the blood was measured to provide a parent input function for kinetic modeling. Arterial blood samples were withdrawn throughout all PET scans, starting with rapid sampling immediately after a bolus injection of [ 18 F]nifene and slowing to 10 minute sampling at late time points. Radioactivity measurements of the whole blood, plasma, and denatured plasma were made with a 2-inch NaI(Tl) well counter cross-calibrated with the PET scanner following our lab's previous published methods. 13 The hematocrit was also measured to correct for the heparinized saline present in the final extract volume. Select samples were used for thin layer chromatography analysis to generate a unique metabolite correction for each subject as described previously. 13 The implementation of the MI compartment model in COMKAT requires the definition of a distinct input function for each injection. To separate the radioactivity from each radioligand injection present in the plasma, the radioactivity concentration curves (before metabolite correction) from 20 minutes after injection until the following injection were fit to decaying exponential functions. Fitting procedures were constrained such that the late decay constant was uniform across all injections for each subject. The resulting fit functions were extrapolated to the end of the study and subtracted from all subsequent injections to generate separate input functions for each injection. The same metabolite correction was then applied to each injection curve to obtain parent [ 18 F]nifene input data expressed as radioactivity (Bq/cm 3 ). The metabolite-corrected radioactivity curve was divided by the specific activity expressed as a function of time to yield an input function (C P ) in units of nifene molar concentration (pmol/ cm 3 ), independent of radioactive decay. Finally, the observed plasma data were fit to the following analytic function: 18 C P ðtÞ ¼ ðc 0 ðt À tÞ À c 1 Þe À g 1 ðt À tÞ þ c 2 e À g 2 ðt À tÞ þ c 3 e À g 3 ðt À tÞ þ c 4 e À g 4 ðt À tÞ ð1Þ where g i represents the different elimination rates of radioligand from the arterial plasma.
PET Image Processing
Dynamic PET data were histogrammed from list mode into time frames of 8 Â 30 seconds, 6 Â 1 minutes, followed by 2 minute frames until 2 minutes before a subsequent injection, with 30 second frames for the remainder of the injection. This binning scheme was repeated for all injections in the study. Sinograms were reconstructed with filtered back projection using a 0.5 1/cm ramp filter, and included corrections for arc, scatter, attenuation, and scanner normalization. The reconstructed images were subjected to a denoising algorithm 19 using a 3 Â 3 Â 3 voxel filtering kernel. The processed images had a final matrix size of 128 Â 128 Â 63 with voxel dimensions of 1.90 Â 1.90 Â 1.21 mm 3 .
Regions of interest were hand drawn with multiple circles on various brain regions. The cerebellum (CB) was defined on early summed images, taking care to focus on grey matter and exclude the vermis region, with a resulting volume of 663 mm 3 . Regions of elevated binding were drawn on late summed images based on areas of high radiotracer uptake. The thalamus was subdivided into the general regions of the antereoventral thalamus (AVT) and lateral geniculate body (LG), with respective volumes of 231 and 161 mm 3 . The frontal cortex (FC) and subiculum (SB), a substructure of the hippocampus, were identified as regions of moderate uptake, and contained volumes of 763 and 314 mm 3 . These regions are shown in Figure 1 . Time-activity curves were extracted from these five regions for analysis.
transfer between these compartments and the plasma is described by the differential equations
The rate constants K 1 (mL/mL per min) and k 2 (1/min) parameterize the transport of ligand from the plasma to the tissue and tissue clearance, respectively. The parameters k on (mL/pmol per min) and k off (1/min) represent ligand binding to the receptor site and dissociation in the in vivo setting. The implementation of MI studies requires unique B(t) and F(t) compartments for each injection. Therefore, a unique set of the above equations is required to describe the ith injection. 21 The modeled PET signal for frame j, C PET j , includes radioactivity from both the B(t) and F(t) compartments at time t summed over all injections, and is expressed as follows:
The constant f V represents the fractional blood volume accounting for the signal from the whole blood measured in the vasculature (A i (t)), and was set to f V ¼ 0.04. Model implementation requires ligand concentrations in units of molar concentrations (pmol/mL); therefore, the specific activity term sa i (t) converts the model concentrations in F i (t) and B i (t) to nondecaycorrected radioactivity units of Bq/cm 3 . Parameters were estimated by minimizing the residual sum of squares between the modeled PET signal and the observed PET signal (PET). The Levenberg-Marquardt optimization algorithm was used to perform this minimization with the following objective function:
The objective function was optimized over J PET frames for given param-
The parameters included in p depended on the step in the fitting procedure (see below). The weighting factor of each PET frame was determined from the time duration by w r,j ¼ (t j À t j À 1 ), and included no contribution from the measured PET data. 22 Model implementation and parameter estimation were performed with COMKAT software. 16 A more in-depth description of the implementation of equations (2)-(5) has been detailed elsewhere. 21 The following assumptions were made to improve parameter identifiability across brain regions:
(1) The nondisplaceable distribution volume (V ND ¼ K 1 /k 2 ) was assumed uniform and unchanging throughout all brain regions. K 1 was allowed to vary across regions to account for regional differences in blood flow, but did not vary over time throughout the experiment. (2) The CB was assumed to contain negligible specific binding, consistent with previous findings examining [ 18 F]nifene in the rhesus monkey. 14 Therefore, CB data were modeled without specific binding compartments (B(t)). (3) The ligand binding and dissociation parameters, k on and k off , were assumed uniform across all regions of specific binding.
These assumptions were implemented in the following three steps:
Step 1: The CB, a region of negligible [ 18 F]nifene binding, was analyzed using a model which omitted B(t) to determine V ND for subsequent analysis of specific binding regions. The objective function in this step was optimized for p ¼ {K 1 , V ND }
Step 2: The high uptake regions of the AVT and LG were analyzed using the fixed V ND value found in Step 1 to obtain estimates of the global parameters k on and k off , as well as the regional parameters K 1 and B max . The objective function was therefore optimized for
Step 3: The k on , k off , and V ND values found in previous steps were fixed to determine K 1 and B max in the FC and SB regions. The objective function was optimized for p
Uncertainties in parameter estimates were examined with Monte Carlo methods as reported previously. 15, 23 The optimized parameters for each study were used to simulate noise-free data. Simulated noise was then introduced according to the equation
where C noise is the simulated time-activity curve with added noise, C fit is the noise-free simulated time-activity curve, N (0,1) is a random number generated from a normal distribution with m ¼ 0 and s ¼ 1, and c 1 and c 2 are scaling factors to obtain noise levels similar to the experimentally observed time-activity curves (10oc 1 o40, 100oc 2 o500). A total of 100 noisy simulated data sets for each subject were constructed and the parameters were estimated. The coefficient of variation (cov ¼ s.d./ mean Â 100%) was measured for each parameter for each subject and recorded.
Parameter Estimation: Scatchard Analysis
Analysis of the PET data included an alternative methodology to measure B max and K Dapp in vivo with PET using a Scatchard-type analysis, which requires equilibrium at the receptor site. 24 As [ 18 F]nifene rapidly establishes transient equilibrium, B max and K Dapp measurements were performed with this method to compare with compartment modeling techniques. Based on previous linearized Scatchard methodologies, 25 the present work evaluated (B/F) at transient equilibrium to regionally estimate B max and K Dapp with the following linearized form of the Scatchard plot:
To determine when transient equilibrium occurred, the parameters resulting from compartment modeling analysis were used to model B(t) and F(t) throughout the experiment. The PET frames when dB(t)/dt ¼ 0, indicating transient equilibrium, were used for Scatchard analysis. PET time-activity curves were 'denoised' by fitting data from 15 minutes after injection to the end of each injection to a decaying exponential function. The total PET signal from the CB was then separated into contributions from each individual [ 18 F]nifene injection by extrapolating the resulting CB fits to the end of the scan and subtracting the extrapolated fits from all subsequent injections. The residual-free CB value for each injection was determined at transient equilibrium and recorded as CB i for the ith injection. The free radioligand concentration F i was calculated as
where SA i is the decay-corrected specific activity of the ith injection. The specific binding fit at transient equilbrium was recorded as S i . The ratio B/F i was evaluated as
was plotted against the y-value,
Linear least-squares fitting was performed on the linearized Scatchard data to determine the slope m and y-intercept y 0 of the plot. B max and K Dapp were estimated as B max ¼ y 0 K Dapp and K Dapp ¼ À 1/m, respectively. The uncertainties of these parameters were determined exclusively based on the regression analysis. This Scatchard analysis was only performed in experiments with three injections of [ 18 F]nifene data (RH1-RH3).
RESULTS

Optimization of Experimental Design
Optimization of MI experimental design revealed that identification of specific binding parameters was most sensitive to the nifene dose in the second injection. A dosage of 0.8 to 2.0 nmol/kg nifene (approximately 70% to 75% receptor occupancy) administered in the second injection optimally determined B max , k on , and k off (see Figure 2A ). The duration of data acquisition beyond 30 minutes for any injection did not improve parameter identification. Uncoupling of B max and k on with the optimal experiment design is shown by the sensitivity functions illustrated in Figure 2B . The resulting experimental protocols used for the four experiments presented herein are detailed in Table 1 .
Compartment Modeling Measurements of B max and [ 18 F]Nifene Kinetic Parameters
All input functions were analytically defined by fitting the blood data to equation (1) . When radioligand was given as a slow bolus (30 to 60 seconds) for injections with a greater cold nifene mass, the third exponential term overparameterized the data (c 4 ¼ 0). A sample fit is displayed in Figure 3 (top). No deviations to the subject's physiologic parameters were observed following the administration of high nifene masses. Parameter estimates obtained with compartment modeling are listed in Table 2 . High identifiability of B max was found in the high binding thalamic regions, where average B max values of 4.8±1.4 and 4.3 ± 1.0 pmol/mL were measured in the AVT and LG, respectively. The parameters k on and k off could not be sufficiently uncoupled, as the correlation coefficient (r kon;k off ) between the two parameters was 40.93 for all experiments. Therefore, measurements of the composite parameter K Dapp ¼ k off /k on are presented. The average value of K Dapp was 2.4 ± 0.3 pmol/mL. In the moderate receptor density regions of the FC and SB, average B max values of 1.2 ± 0.4 and 1.2 ± 0.3 pmol/mL were observed. The uncertainty of each parameter estimate was estimated with Monte Carlo methods. These simulations found the highest variability in the B max parameters (cov ¼ 12% to 15% for all regions) and K Dapp (cov ¼ 18%). Sample fits of the measured PET time course for three regions (CB, AVT, and SB) are included in Figure 3 .
The sensitivity curves in Figure 2B showed little parameter uncoupling during the third injection. Therefore, compartment modeling parameter and uncertainty analysis was performed on the first two injections of data from experiments with three injections. A comparison of the resulting values from the two injection and three injection analyses yielded estimations of B max and K Dapp within 1s of the values determined with the full scan of data. No significant bias was apparent in the thalamic specific binding parameters ( Figure 5B ). Figure 4 . Using uncertainties from the linear fit, cov values of 17% to 30% and 14% to 28% were found for B max and K Dapp , respectively, in thalamic regions. Estimates of B max and K Dapp with this graphical analysis are compared with the MI technique, as shown in Figure 5A . As the three-point Scatchard plots tended to exhibit nonlinearity, two-point Scatchard plots were generated for experiments RH1-RH3 in each of the specific binding regions. A slight positive bias in the B max estimations was apparent with the two-point Scatchard plots relative to the values found with the compartment modeling ( Figure 5C ). 9 Although these experiments were performed in a variety of species with different methodologies, the similarities within order of magnitude indicate agreement with the B max values presented herein.
DISCUSSION
A first precise measure of [ 18 F]nifene K Dapp , 2.4±0.3 pmol/mL, is reported. This value compares well with our previous work, which preliminarily estimated a K Dapp of 3 ± 1 pmol/mL for [ 18 F]nifene in the rhesus monkey with a Scatchard-like analysis assuming the same K Dapp across all subjects. 13 The different affinities for nAChR a4and b2-inclusive subtypes likely influenced the observed K Dapp value. As nifene lacks the sensitivity to differentiate between these subtype affinities, the observed value is likely most representative of [ 18 F]nifene's K Dapp for the a4b2 subtype because of its high thalamic density relative to other nAChR subtypes. The only other 
Analysis with Compartment Modeling
Successful identification of kinetic parameters with MI experiments requires precise experimental design. The D-optimal criterion, which focused on uncoupling B max , k on , and k off in the thalamus, determined the optimal cold ligand dose and injection times. The resulting protocol uncoupled B max from k on and k off with the administration of a nifene dose eliciting a peak transient occupancy of 70% to 75% in the second injection. The optimization results further suggested that a roughly 6 nmol/kg nifene dose (490% occupancy) given in the third injection would separately identify k on and k off . In practice, however, these parameters were not uncoupled during analysis of the experimental data (as shown in Figure 2B ), as initial simulations underestimated k on and k off .
To provide insight into k on and k off values, a family of simulated thalamic PET curves was generated using the measured parameter values from Table 2 while incrementing k on and k off with K Dapp fixed to compare with the observed PET data. This brief analysis revealed that k off values slower than 0.1 1/min significantly reduced the quality of fit, making this a lower bound for k off for this experimental design. In this work, the experiment with the lowest correlation coefficient between k on and k off (RH3, r kon;k off ¼ 0:93) resulted in k off ¼ 0.32±0.07 1/min and k on ¼ 0.14 ± 0.03 mL/pmol per min, yielding speculative values likely biased by parameter coupling in the fit. For comparison 2-[ 18 F]FA was found to have a k off value of 0.33± 0.07 1/min. 11 The fast k on and k off values partially explain the inability to separate the two parameters. The close similarity in k 2 (B0.2 1/min) and k off (40.1 1/min) also likely contributed to the inability to identify uniquely k on and k off , as the two transfer routes occur at similar rates that the model cannot readily distinguish.
The specific binding parameters B max and k on were coupled to k 2 because of the fast ligand binding and dissociation rates of [ 18 F]nifene. To examine the repercussions of an unconstrained V ND in regions of specific binding, a model was implemented to simultaneously estimate K 1 , V ND , B max , and K Dapp exclusively in the AVT and LG. This model configuration yielded an 11% inflation of V ND and reductions in B max ( À 20%) and K Dapp ( À 16%). Therefore, to minimize potential parameter coupling between the radioligand delivery and specific binding parameters, V ND was measured in the CB, and subsequently assumed constant throughout the brain by fixing V ND (but not K 1 ) in regions with specific binding. The assumption of a uniform V ND is commonly made with a reference region graphical analysis techniques. 26 When data exclusively from the CB was modeled to measure separate V T values for each injection, these values agreed within 6% with no appreciable correlation of V T with nifene mass, justifying the omission of specific binding in modeling the CB.
The initial model for parameter estimation was constructed to generate unique B max , k on , and k off values for each region; however, high coupling of B max and K Dapp in the cortical regions resulted in unidentifiability of those parameters in the FC and SB (r Bmax;kon 40:9). Separate K Dapp values in the AVT and LG were within 10% of each other, suggesting K Dapp may be uniform in the thalamus. The assumption of a uniform K Dapp was extended to the FC and SB to provide preliminary estimations of B max in the cortical regions. A similar approach was used in experiments estimating extrastriatal D2 B max by fixing k off to the value observed in the basal ganglia. 27 Assuming a global K Dapp represents a limitation in the present results, as our group has previously shown regional K Dapp variations in experiments examining the serotonin system with MI techniques. 28 Consequently, the extrathalamic B max estimations may be biased if endogenous concentrations of acetylcholine vary across different brain regions. A different experimental design explicitly optimized for cortical regions is necessary to properly measure B max and K Dapp in the cortex.
Uptake of [ 18 F]nifene into the tissue occurred rapidly, as an average K 1 value of 1.0 ± 0.1 mL/mL per min was observed in the CB with values of 0.8±0.2 mL/mL per min found in both the AVT and LG. These high K 1 values are consistent with complete extraction of radioligand from the plasma to tissue. Previous in vitro studies have indicated that transfer of 2-[ 18 F]FA across the blood-brain-barrier (BBB) principally occurs because of free diffusion. 29 Although [ 18 F]nifene (log P ¼ À 0.5; 12 ) is more lipophilic than 2-[ 18 F]FA (log D ¼ À 1.5; 29 ), both radioligands exhibit low lipophilicity, which predicts slow diffusion rates across the BBB. 30 The order of magnitude variation in K 1 between the two radioligands, however, suggests the possibility of a transport mechanism to account for the fast uptake rates of [ 18 F]nifene. One possible candidate for this mechanism is the BBB amine transporter. 31 Previous studies have found that another a4b2* nAChR radioligand, [ 18 F]flubatine (formerly [ 18 F]NCFHEB), also interacts with this transporter. 32 We investigated using a model with separate K 1 parameters for each injection to account for high mass potentially altering transfer rates of [ 18 F]nifene across the BBB. This model reduced parameter identifiability while yielding K 1 estimates that did not correlate with administered nifene mass. Therefore, K 1 was assumed unvarying throughout the entire experiment. The BBB amine transporter is an area of interest for future experiments aimed at improving understanding of the passage of [ 18 F]nifene across the BBB. 33 As the third injection of data could not uncouple k on and k off , data from only the first two injections of the three injection experiments were analyzed with the same model. This analysis yielded B max and K Dapp values consistent with results from analyzing the full three-injection data set, as shown in Figure 5B . The precision of the two-injection analysis was comparable, with average B max cov values of 15%, whereas K Dapp cov values were 19%. A slight underestimation of the specific binding parameters was observed with the two-injection analysis; however, the estimates were within 1s of the three-injection parameter values. Our previous work included two experiments with two-injection [ 18 F]nifene protocols of appropriate mass to provide approximations of B max and K Dapp . 13 One experiment was not included in this work because of different blood sampling methods, whereas the other was included (M2 from ref. 13 corresponds to RH4 here). Modifications to the data processing of this subject (e.g., different regions of interest, input function interpolation) resulted in estimates of BP ND and V ND that are comparable but not identical to previously reported values. This subject (RH4) had the lowest B max value and was also the oldest, with an age of 12.9 years compared with other subjects (4.6 to 5.2 years). Although only four subjects were reported here, this lower receptor density may result from differences in age groups. 34 Analysis with the Scatchard Method MI experiments provide measurements of B max in a nonequilibrium setting, which distinguishes this method from Scatchard-like methods requiring equilibrium for successful B max measurements. The optimal MI experimental design for measurement of B max and K Dapp with [ 18 F]nifene, however, included transient equilibrium for each injection because of the fast kinetic properties of this radioligand. Consequently, measurements of B max and K Dapp were also made with a Scatchard methodology to compare directly the compartment modeling method with a method that did not require blood sampling. It should be stressed, however, that the selected doses for the present experiments were based on the optimal design for MI (nonequilibrium) analysis rather than Scatchard analysis. Therefore, alternative dosages are likely more appropriate for experiments utilizing a Scatchard analysis.
The resulting Scatchard plots, shown in Figure 4 , yielded B max values compatible with compartment modeling results in the thalamic regions in two experiments (RH2 and RH3). Experiment RH1 exhibited a nonlinear trend resulting in overestimations of B max and K Dapp ; however, the administered nifene dose in the third injection for this experiment more than doubled the mass given for RH2 and RH3 (see Table 1 ). We conclude that this dose (17.4 nmol/kg) saturated the receptors and yielded unreliable results. Indeed, the third injection for RH2 and RH3 may have saturated the extrathalamic regions, indicated by the slight nonlinearity in the Scatchard plots and large positive bias in B max compared with compartment modeling methods. A two-point Scatchard analysis, which ignored data from the third nearsaturation injection to avoid the resulting nonlinearities, was also performed. Although two-point Scatchard measurements are vulnerable to inaccuracies resulting from fitting two points to a line, this brief analysis estimated B max values in better agreement with those measured with compartment modeling ( Figure 5C ). Lower nifene dosages, yielding receptor occupancies of roughly 30% to 50% and 70% to 75%, respectively, for each injection, may yield improved B max and K Dapp measurements with the three-point Scatchard analysis method. A bolus-infusion protocol achieving true equilibrium could also improve the accuracy and precision of this method, 25 but at the expense of increased experimental complexity.
It is difficult to compare directly the presented analysis techniques as the experiments were optimized for compartment modeling analysis but not Scatchard analysis. Based on the available data, the two-injection compartment model paradigm provided the best method for measurements of B max and K Dapp with a better combination of experimental simplicity and parameter precision. Reducing the experimental protocol from three injections to two injections lessened the duration of scanning procedures to 90 minutes of data acquisition, and simulations suggest this could be further shortened to 70 minutes. Conversely, accurate estimates of B max and K Dapp with Scatchard analysis would require at least three injections of [ 18 F]nifene and 120 minutes of scanning. The compartment modeling techniques also showed higher parameter precision. Although the fast kinetics of [ 18 F]nifene prevented unique identification of k on and k off with the compartment modeling analysis, this technique yielded excellent identification of B max (r Bmax;kon o0:3), giving a high degree of confidence in the presented measurements. Theoretical advantages of MI techniques for measurement of B max and K Dapp are further discussed elsewhere. 21, 35 Applicability to Human Studies The separate evaluation of a4b2* nAChR B max and K Dapp is important for human translation for research applications in a variety of complex neuropsychiatric processes. For example, these measurements would improve the understanding of longitudinal changes undergone by acetylcholine receptors, ligand-receptor affinity, and synaptic acetylcholine concentrations in the progression of Alzheimer's disease. 3 Information regarding how receptor density and synaptic acetylcholine are differentially modulated during tobacco exposure and abstinence could lead to improved design of smoking cessation treatments. 5 Similar experiments could also improve understanding and treatment of depressive disorder. 4 Future toxicological and pharmacological measurements of nifene are needed to determine if nifene doses inducing significant receptor occupancies would be ethical in humans. The 0.6 nmol/kg dose used for the present experiments resulted in a4b2* nAChR occupancies of roughly 70%; however, saturation of these receptors has been reported with no adverse side effects in 2-[ 18 F]FA smoking studies. 36 The rhesus monkey appears to be a unique species with negligible a4b2* binding in the CB, as baboons and humans have detectable 2-[ 18 F]FA specific binding in this region. 11, 37 Alternative reference regions, such as the corpus callosum or pons, were not evaluated in this work because of the absence of anatomical MRI data to aid in region identification. In the absence of a valid reference region, modifications to the modeling methods presented herein may be necessary for accurate parameter measurements in human studies. Compartment modeling techniques simultaneously incorporating data from regions of low [ 18 F]nifene uptake with high binding regions may more precisely aid in the identification of a global V ND without an explicit reference region. Alternatively, previous PET and SPECT experiments found that smoking to satiety resulted in a4b2* nAChR occupancies of 70% to 100%. 36, 38 These data suggest the possibility of incorporating a complete displacement dose of nicotine to regionally determine V ND in MI studies.
CONCLUSION
This work presents an in vivo measurement of a4b2* nAChR B max in the rhesus monkey and a first measurement of K Dapp for [ 18 F]nifene using MI techniques. Experiments consisting of two injections in 90 minutes or less precisely identified these parameters, which reduces the experimental complexity from more traditional three-injection designs. Therefore, [ 18 F]nifene enables simplified methods of measuring a4b2* nAChR B max , allowing for interrogation of this receptor system in disease models and alterations to synaptic levels of acetylcholine because of substance abuse or therapeutic drugs. 
